Project Grant R01HL171495
Award Date
8/15/24
Completion Date
5/31/28
Dollars Obligated
$726K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45221, USA
Similar Awards
This $408,599 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the TGF-beta/SMAD3 pathway in endothelial damage and cardiac remodeling caused by doxorubicin chemotherapy. The research aims to assess how doxorubicin-induced endothelial reprogramming via this pathway contributes to the development of cardiomyopathy, and whether suppressing SMAD3...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $684,794 to the University of California, Merced to conduct research on the role of the blood vascular system and endothelial cells in the regeneration of the thymus after cytotoxic treatments. The key objectives are to utilize novel intravital imaging and oxygen microscopy techniques to (1) characterize the native thymic vascular...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $144,362 to the University of Pittsburgh to fund a research project focused on understanding the role of the CYB5R1 enzyme in regulating ferroptosis, an iron-dependent form of cell death, in endothelial cells. The project aims to elucidate the mechanisms by which CYB5R1 protects endothelial cells from ferroptosis, and to determine the...
This Project Grant award of $734,607 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to elucidate the key endothelial mechanisms that direct hematopoietic stem cells (HSCs) across the blood vessel wall and into their niche. The research, conducted by Boston Medical Center Corporation, will use high-resolution live cell imaging, structure-function studies, and in vivo proximity-dependent biotinylation in zebrafish to define the endothelial...
This Project Grant award for $547,020.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to establish an Organoid-AI system for assessing cardiotoxicity induced by Tyrosine Kinase Inhibitors (TKIs) used in cancer treatment. The central goal is to develop a comprehensive in vitro human model using Pluripotent Stem Cell-derived Vascularized Cardiac Organoids (VCOs) to accurately predict and phenotype...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the University of Illinois aims to investigate the molecular mechanisms by which the cancer drug sunitinib induces vascular dysfunction. The $701,890 award will fund research to: 1) define how sunitinib translationally regulates the gene SND1, 2) dissect the role of SND1 in mediating endothelial tolerance against sunitinib through its interaction with UBE2N in...
This Project Grant award of $540,856 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to understand the gene regulatory networks that control endocardial-specific gene expression. The key objectives are to: 1) Identify transcriptional regulators of endocardial-restricted gene expression, 2) Determine how valve-restricted gene expression is achieved, and 3) Define the regulation and function of the SLC16A2 gene during heart injury...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $2,060,460 to the University of Louisville to investigate a dual-targeting compound that may prevent doxorubicin-induced cardiotoxicity. The research aims to optimize the protective effects of this compound against cardiotoxicity in tumor-free and tumor-bearing mice, determine if it prevents cardiotoxicity by activating CXCR7/AMPK to prevent cardiac cell death and...
This Project Grant award of $1,102,957, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports a research program to investigate the relationship between cancer and cardiovascular disease. The program aims to: 1) map causal associations and genetic links between the two disease states; 2) use advanced animal models to prove that cancer can directly promote atherosclerosis; and 3) establish a drug discovery pipeline to identify potential...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $149,948 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University to investigate the role of p53 signaling in endothelial-to-mesenchymal transition and its impact on radiation-induced coronary heart disease. The 2-year project aims to utilize human-induced pluripotent stem cells and transgenic mouse models to elucidate the functional and molecular alterations in the...